Replies to post #2820 on Revance Therapeutics Inc (RVNC)

[mouton29]

Later they project some modest (pitiful?) revenue from therapeutic indications.

For cerivcal dystonia, they project "2025/2030 unadjusted sales of $22mn/$39mn and apply a 70% POS."

For upper limb spasticity, about the same, $24 million in 2025 and $82 million in 2030.